Abata Therapeutics Receives FDA Fast Track Designation for ABA-101 for the Treatment of Progressive Multiple Sclerosis Abata Therapeutics Receives FDA Fast Track Designation for ABA-101 for the Treatment of Progressive Multiple Sclerosis

Abata Therapeutics Announces Strategic Investment from Bristol Myers Squibb Supporting Advancement of its Treg Cell Therapy Pipeline into Clinical Development Abata Therapeutics Announces Strategic Investment from Bristol Myers Squibb Supporting Advancement of its Treg Cell Therapy Pipeline

Abata Therapeutics Announces FDA Clearance of Investigational New Drug Application for Clinical Evaluation of ABA-101 in Progressive Multiple Sclerosis Abata Therapeutics Announces FDA Clearance of Investigational New Drug Application for Clinical Evaluation of ABA-101 in Progressive Multiple Sclerosis